We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Sareum Announces Research Collaboration with PIramed


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sareum Announces Research Collaboration with PIramed"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Sareum Holdings plc has announced that it has entered into a significant research collaboration with PIramed Ltd to discover targeted drug therapies for the treatment of immune inflammatory diseases.

Under the terms of this collaboration, which is scheduled to run for a period of up to 18 months, Sareum will provide multi-disciplinary research teams with the aim of generating drug lead series for further development by PIramed.

This involves the generation of chemical material using Template Screening, Sareum’s fragment-based drug discovery technology, and optimisation into drug leads using Sareum’s automated medicinal chemistry platform.

In return, Sareum will receive undisclosed research fees and success milestone payments, including additional milestone payments if compounds arising out of the collaboration advance to clinical development.

This is the third multi-disciplinary drug discovery collaboration Sareum has signed this year. Sareum announced agreements of similar scope with Organon and Idenix in January and February 2006.

Commenting on this announcement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "This major collaboration with PIramed is a further endorsement of Sareum’s leading position in structure-based drug discovery."

"We look forward to successfully using our multi-disciplinary platform to deliver drug candidates against these important disease targets."

Advertisement